These replicons were engineered to express cytokines like XCL1, IL-12 or FMS-like tyrosine kinase 3 ligand (Flt3L), or checkpoint inhibitors and demonstrated strong T cell-dependent anti-tumor activity in vivo.10 Here, XCL1 is linked to neoplasm.